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formulations (ie, Levopar capsules [Hexal], Levodopa comp. B 
STADA [STADApharm] and Levobens-Teva capsules [Teva]). Shape, 
color, appearance, and hardness (tablets) or surface, color, imprint, 
and content (capsules); mass (tablets) or fill-mass (capsules); content, 
degradation products, other unspecified impurities, disintegration 
time and dissolution after 30 minutes were assessed by standard phys-
ical and chemical laboratory tests along the original specifications.
Results: For all 7 generic products, at least 1 of the tested parameters 
fell outside the Madopar®/Prolopa® “shelf-life” specifications for 
the reference. Content requirements were unmet by 2 tablet formu-
lations for L-Dopa (specs: 100 mg ± 5%; test results: –5.6% and 
–7.6%) and for benserazide (specs: 28.5 mg ± 5%; –6.6% and 8.4%). 
Average mass (specs: 275 mg ±3%) was not reached for 2 tablet 
formulations (3.3%), and average fill mass (specs: 150 mg ±5%) was 
not reached for 3 capsule formulations (48.2%, 99.1%, 99.3%). The 
content of 1 capsule was brown (specs: light-beige). The quantity of 
2 benserazide degradation products (Ro 04-1419 and Ro 08-1 580; 
specs: max. 0.49%) was out of limits (0.62%) in 1 of the capsulated 
formulations.
Conclusion: All 7 analyzed generic L-Dopa/benserazide products 
exhibited at least 1 deviation compared with the shelf-life specifica-
tions of Madopar®/Prolopa®125. Deviations for the active ingredi-
ents ranged from 8.4% (benserazide) to –7.6% (L-Dopa) in 2 tablet 
products, which may result in clinical consequences for long-term 
administration. Furthermore, 2 of the degradation products were 
measured in excess of 26.5% above specification standards, posing a 
potential safety concern for treated patients. These results should lead 
to caution when prescribing a generic of Madopar®/Prolopa®, and 
also invite further investigations of a more comprehensive approach, 
from both pharmaceutical and clinical perspectives.
Disclosure of Interest: G. Vital-Durand: Employee of manufac-
turer. I. Arnet: None declared. U. Gasser: None declared. A. Fischer: 
Employee of manufacturer.
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Introduction: Although no clinically relevant resistance to the only 
schistosomicidal drug praziquantel (PZQ) has been described to date, 
development of drug resistance remains a growing threat. Calotropis 
(C.) procera, Ficus (F.) elastic, and Zingiber (Z.) officinale are well-
known medicinal plants and have been traditionally used for many 
diseases.The present work aimed to evaluate the antischistosomal 
activity of these plant extracts against Schistosoma (S.) mansoni.
Patients (or Materials) and Methods: Male mice exposed to 80 ±10 
cercariae/mouse were divided into 2 batches. The first was divided 
into 5 groups; (I) infected untreated, while groups from (II–V) were 
treated orally (500 mg/kg for 3 consecutive days) by aqueous stem 
latex and flowers of C procera, latex of F elastica and ether extract of 
Z officinale, respectively. The second batch was divided into 4 com-
parable groups (except Z officinale–treated group) similarly treated 
as the first batch in addition to the antacid ranitidine (30 mg/kg) 1 
hour before extract administration. Safety, worm recovery, tissues 
egg load, and oogram pattern were assessed.
Results: Results indicate that C procera latex and flower extracts 
are toxic even in small doses before washing off toxic rubber. 
Z officinale extract produced numerical insignificant decrease 
(7.26%) in S mansoni worms. When toxic rubber was washed off 
and the antacid ranitidine used, C procera (stem latex and flowers) 
and F elastica latex extracts revealed significant antischistosomal 
worm reductions by 45.31%, 53.7%, and 16.71%, respectively. 
Moreover, C procera extracts produced significant reductions in 
tissue egg load (≈ 34%–38.5%) and positively affect the oogram 
pattern.
Conclusion: The present study may be useful to supplement informa-
tion with regard to C procera and F elastica antischistosomal activity 
and provided a basis for subsequent experimental and clinical trials.
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Introduction: Dyes containing an azo (N = N) group are widely 
used in the food, pharmaceutical, cosmetic, and textile industries to 
provide color to products. Reports on the potential carcinogenicity 
of specific azo dyes, like Sudan I, has resulted in it being banned from 
use as a food additive. The association of the azo dyes, Tartrazine and 
Sunset Yellow, with the attention-deficit/ hyperactivity syndrome has 
further vilified azo dyes and focused scientific interest on its potential 
harmful effects. In an attempt to improve understanding of the azo 
dyes and in a search for new lead compounds for cancer drug devel-
opment, we have investigated the effects of a panel of 24 azo dyes on 
the survival of cancer cell lines.
Patients (or Materials) and Methods: A T-cell leukemic cell line 
(Jurkat) and a breast cancer cell line (MCF7) was maintained asepti-
cally in culture according to standard procedures. Cell were exposed 
to azo dyes, and their effects on cell growth and viability was deter-
mined by [3H]-thymidine incorporation into DNA. Labeled thymi-
dine incorporation into DNA was measured by precipitating DNA 
on glass fiber filtermats followed by liquid scintillation counting. Log 
dose-response curves were then constructed using the Graph-Pad 
Prizm software package.
Results: Four of the 20 compounds inhibited the proliferation of 
both Jurkat and MCF7 cells with IC50 values ranging between of 28 
and 82 micromoles. MCF7 cells were inhibited by Eriochrome Blue 
Black B and Eriochrome Black T with IC50 values of 28.43 (1.13) 
and 37.22 (4.6) µM, respectively. Jurkat cells were most sensitive to 
Eriochrome Black T with an IC50 value of 38.69 (2.26) µm compared 
with Eriochrome Blue Black with an IC50 value of 79.95 (1.01). 
Furthermore, Palatine Chrome Black 6BN and 4-phenylazophenol 
inhibited Jurkat cells with IC50 values of 82.04 (1.02) and 72.61 
(1.03) µM, respectively. These data support previous reports regard-
ing the anticancer properties of Eriochrome Black T.
Conclusion: This preliminary study identified 4 azo dyes whose 
structures can serve as lead compounds for new cancer drug devel-
opment. Further studies will investigate the effects of azo dyes on cell 
lines derived from other cancers and determine the potential of the 
active dyes to induce apoptosis.
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Introduction: Mavoglurant is a noncompetitive antagonist at the 
metabotropic glutamate receptor 5 (mGluR5) currently being inves-
tigated as oral treatment of Parkinson’s disease–associated levodopa-
induced dyskinesia (PD-LID) and fragile X syndrome (FXS). This 
study evaluated the impact of single therapeutic and supratherapeutic 
intravenous (IV) doses of mavoglurant on the QTc interval duration 
in healthy subjects in compliance with the ICH E14 guideline.
Patients (or Materials) and Methods: In a pilot-phase, the safety 
and tolerability of single, ascending IV doses of 25 mg, 37.5 mg, 
and 50 mg of mavoglurant was assessed in 36 healthy subjects (n = 
12 per dose level). Subsequently, a randomized, placebo- and active-
controlled, 4-period, single-center, crossover thorough QTc study has 
been conducted in 76 healthy subjects with the following single-dose 
treatments: therapeutic and supratherapeutic dose of mavoglurant, 
400-mg moxifloxacin, and placebo. Mavoglurant was administered 
intravenously in a double-blind fashion, while the positive control 
moxifloxacin was orally administered in an open-label fashion. 
Holter ECG monitoring was performed up to 24 hours postdosing, 
and QTc data were derived from triplicate ECGs extracted at 3 pre-
dose (= baseline) and 12 postdose time points.
Results: An acceptable safety and tolerability of mavoglurant was 
confirmed at single IV doses of 25 mg, 37.5 mg, and 50 mg according 
to predefined criteria. Hence, doses of 25-mg and 50-mg mavoglurant 
were selected as therapeutic and supra-therapeutic dose for the core 
TQT study. The upper bound of the 90% 2-sided CI of the placebo 
and baseline-corrected QTcF (= Δ Δ QTcF) did not exceed 10 ms at 
any postdose time point for both doses of 25-mg and 50-mg mavo-
glurant. The maximum QTcF prolongation of 1.98 ms (90% CI, 
0.58–3.38) on 25 mg and 1.49 ms (90% CI, 0.10–2.88) on 50 mg 
were observed 3 hours’ postdosing. The PK/PD analysis confirmed 
the lack of an association between AFQ056 plasma concentrations 
and Δ Δ QTcF data over the entire range of Cmax data at 25-mg and 
50-mg mavoglurant (r2 < 0.01). An outlier analysis showed no sub-
jects with newly identified QTcF intervals > 480 ms or any QTcF pro-
longation > 60 ms compared with baseline in any treatment group. 
Study validity was confirmed given that the lower bound of the 90% 
CI of Δ Δ QTcF for moxifloxacin was > 5 ms at 4 predefined postdose 
time points (1, 2, 3, and 4 hours) (Bonferroni-adjusted P < 0.0125).
Conclusion: In this thorough QTc study, the lack of any clinically 
relevant QTc prolongation was demonstrated for both therapeutic 
and supratherapeutic single IV doses of 25-mg and 50-mg mavo-
glurant.
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Introduction: In this study, an in vitro bioassay of 1,5-dimethyl 
citrate monohydrate was carried out; 1,5-dimethyl citrate mono-
hydrate is a hydrated citric acid derivative with molecular formula 
C8H12O7·H2O isolated from Mangifera indica fruit
Patients (or Materials) and Methods: To support the hypothesis that 
the compound may have effect on smooth muscles, the activity of this 
pure compound on the longitudinal smooth muscles of isolated guinea 
pig ileum, rabbit jejunum, and guinea pig trachea was determined.
Results: Graded doses of the compound (0.5 mg/mL and 1 mg/
mL) showed a dose-dependent increase in contraction of the lon-
gitudinal smooth muscle of the isolated guinea pig ileum similar to 
histamine, and this contraction was antagonized by mepyramine. 
The compound was thus speculated to be a histaminergic agonist, 
which acts on the H1 histamine receptors found on smooth muscles. 
Activation of these H1 receptors in smooth muscle cells causes an 
increase in phosphoinositol hydrolysis and increase in intracellular 
calcium which brings about contraction of intestinal smooth muscle. 
The compound, however, at a concentration of 1 mg/mL produced 
no remarkable effect on the rabbit jejunum. Because the compound 
did not produce any remarkable effect on the rabbit jejunum, it is 
possible to speculate that the compound 1,5-dimethyl citrate mono-
hydrate at 1 mg/mL does not activate the cell specific receptors on 
the smooth muscles neither does it interact with voltage-operated 
Ca2+ channel. The compound also at a concentration of 5 mg/mL 
produced no appreciable response on guinea pig trachea.
Conclusion: This suggests that the compound may not interact with 
the receptors present to cause any remarkable response.
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Introduction: Melitor®/agomelatine/ is an melatonergic antidepres-
sant developed by the pharmaceutical company Servier. It is marketed 
for the treatment of major depressive disorder and has been reported 
to have a reduced level of sexual side effects as well as discontinuation 
effects compared with some other antidepressants. Agomelatine may 
also have positive effects on sleep.
Patients (or Materials) and Methods: According to Serbian Law 
on Medicinal Products and Medical Devices, regulatory procedural 
steps taken for getting Marketing Authorisation Approval in Serbia, 
started on 2011 year. Assesment of submitted documentation/Module 
1-5 Common Technical Document/ lasted longer, because of waiting 
additional regulatory data requested from the manufacturer.
Results: After evaluation submitted documentation by ALIMS’s 
Assessors, and re-evaluation the same documentation by the 
experts that are in Advising Working Group for medicinal products 
of Medicines and Medical Devices Agency of Serbia , the ALIMS 
requested again additional data related to efficacy and safety of this 
drug. The explanation of this action was: Mechanism of action of 
agomelatin does not support the pharmacotherapeutic principles of 
threating major depression.
Results of submitted clinical trials did not prove the efficacy of 
this drug. After oral administration, pharmacokinetic results showed 
nonlinearity in wide dose range and rough proportionality inside 
the therapeutic dose range. As postmarketing follow-up reports, 
applicant for getting Marketing Authorization Approval submitted 
4 Periodic Update Repotrs / PSURs/. On the basis of these PSURs, it 
could not be concluded that benefit/ risk assessment of agomelatin 
in the treatment of major depression is positive.
Conclusion: After several meetings, relevant ALIMS’ experts sug-
gested refusal of Melitor® registration. The regulatory story is still 
lasting, because applicant lodged the complaint on ALIMS’ decision 
